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AbSTrACT
Objectives: We investigate how concurrent high-risk (hr) HPV (human papillomavirus) genotypes affect CIN2-3 risk and 
evaluate the relationship of different genotype combinations with cervical epithelial lesions.
Material and methods: This study included HPV positive patients between the ages of 30 and 60 who underwent 
liquid-based cervical smears and HPV screening through community-based, cervical cancer screening programs between 
June 2015 and June 2017. The impact of the increase in hrHPV types was calculated by estimating how it changed the 
odds ratio of CIN2-3 risk.
results: The rate of multiple concurrent HPV infections was 48.7% in the CIN2-3 group and 58.4% in the CIN1 group. Among 
patients in the CIN2-3 and CIN1 groups, the most common HPV coinfection was respectively HPV 16+31 and HPV 16+51. The 
HPV 51 ratio in CIN1 patients was 28.9% and the HPV 51 ratio in the CIN2-3 patient was 6.6%. With every increase in the 
number of hrHPV infection types, the frequency of CIN2-3 decreased [OR: 0.72, 95% CI: 0.54-0.95]. For all hrHPV combina-
tions, the addition of HPV 16 was associated with a higher risk of CIN2-3.
Conclusions: An increase in number of hrHPV types is associated with lower CIN2-3 risk. Further cohort studies with larger 
samples are needed to clarify this relationship. The available evidence suggests that HPV 16 genotype plays an important role 
in patients with high-grade cervical lesions and has a negative impact on the cervix in concurrent multiple HPV infections.
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INTrODUCTION
Cervical cancer is the second most common type of 
cancer among women worldwide and the leading cause 
of mortality in developing countries. Virtually all cases of 
cervical cancer are attributable to human papilloma virus 
(HPV) infection caused by high risk genotypes, with HPV 
16 accounting for approximately 50%, HPV 18 for 20%, and 
HPV 31, 33, 45 and 52 a total of 19% of the cases [1, 2]. 
In assorted communities, the shares of these different types 
of HPV vary. As a consequence of the prevalence of HPV, 
many countries have added HPV genotyping to cervical 
cytology in the community-based cervical cancer screen-
ing programs. 
Although screening and treatment management for 
high-risk HPV (hrHPV) genotypes have well-defined guide-
lines, the issue of follow-up and treatment strategy in the 
presence of concurrent multiple HPV genotypes is less es-
tablished. Co-infections of HPV types are common and have 
been documented in several epidemiological studies [3–6]. 
However, the data on the co-infections is limited, and the 
clinical meaning of the condition and its effect on the risk of 
cervical cancer and precancerous cervical lesions is not clear.
In this study, patients who were referred to our clinic for 
colposcopies based on community-based cervical cancer 
screening program and who were found to have cervical 
intraepithelial lesion (CIN) 1 and CIN2-3 after cervical bi-
opsy were included. We investigate how an increase in the 
number of the high-risk HPV genotypes affect CIN2-3 risk 
and evaluate the relationship of different genotype combi-
nations with cervical epithelial lesions. 
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MATErIAL AND METHODS
Within the scope of community-based cervical cancer 
screening program; we applied colposcopic cervical bi-
opsy (criteria were one of the following a) HPV 16, 18 posi-
tive; b) Cervical cytology normal or abnormal, high-risk HPV 
positive; c) cervical cytology abnormal) to 840 patients who 
underwent fluid-based cervical smear and HPV genotyp-
ing between June 2015 and 2017 and referred to our clinic 
— Bakirkoy Dr. Sadi Konuk Training and Research Hospital, 
Department of Obstetrics and Gynecology, for colposco-
pies. Approval was granted for the present study from the 
Local Ethics Committee.
All cervical cytology samples were obtained through 
liquid-based Pap tests (Thin Prep Pap Tests). The liquid-based 
Pap tests were then reported according to the 2001 Bethes-
da system. In order to identify HPV genotypes, we ana-
lyzed cervical specimens using Hybrid Capture 2 for HPV 
16, 18 and the other hrHPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 
53, 56, 58, 59, 66 and 68) types.
According to the cervical cytology results and HPV geno-
typing, colposcopies were performed on the patients based 
on the guidelines of the American Society for Colposcopy 
and Cervical Pathology (ASCCP). Histological specimens 
were taken using a colposcopy-guided biopsy. A random 
biopsy was performed at the squamo-columnar junction 
of each patient who displayed no lesions caused by the 
colposcopy. All colposcopic examinations were performed 
by two gynecological oncology specialist, and the biop-
sies and final histological excision results were reviewed 
by one or two experienced gynecological pathologists. For 
all patients, demographic characteristics and the results of 
biopsies taken during colposcopies were recorded.
A new classification system, LAST, was used to identify 
the cervical lesions [7]. In this system, cervical lesions were 
classified as either high-grade (CIN2 and CIN3) or low-grade 
(CIN1). Follow-ups and treatments of the patients were man-
aged according to the 2012 ASCCP guidelines.
The present hrHPV genotypes of patients with positive 
cervical intraepithelial lesions were recorded. All specimens 
with two or more detected HPV genotypes were considered 
as concurrent HPV infections.
The primary outcome measure is CIN2-3 risk compared 
to CIN1 group. The impact of the increase in hrHPV types 
was calculated by estimating how an increase in the num-
ber of concurrent hrHPV types changed the odds ratio of 
CIN2-3 risk.
Statistical analysis
Statistical Package for the Social Sciences, Version 
23.0 (SPSS Inc., Chicago, IL) was used for the statistical anal-
ysis. Kolmogorov Smirnov and Shapiro–Wilks tests were 
conducted to check the distribution of the data. Levene’s 
test was used to assess the homogeneity of variances. For 
comparison of demographic characteristics, Mann-Whitney 
U test and Pearson Chi-Square Test were performed as ap-
propriate. Bivariate logistic regressions were conducted for 
assessing CIN2-3 risk. CIN1 group was accepted as the refer-
ence group. Due to the limited number of patients included 
in the study, the model was adjusted for only demographic 
characteristics having p-value lower than 10% in the logistic 
regression model. Parity and the number of hrHPV types 
were the only variables that satisfied these criteria. Pearson 
Chi-Square Test or Fisher’s Exact Test were used to compare 
the distribution of hrHPV types among different types of 
cervical lesions. 2-tailed p-values below 5% were assumed to 
be statistically significant. Data were presented as Mean ± SD, 
Median [Minimum-Maximum] or number (percentage).
rESULTS
Colposcopic cervical biopsy revealed no dysplasia 
in 591 patients. We found cervical intraepithelial lesions 
in 249 patients. Of these 249 patients, 76 (30.5%) had 
CIN2-3 and 173 (69.5%) had CIN1. The distribution of sin-
gle and concurrent hrHPV infections due to various hrHPV 
genotypes is summarized in Figure 1.
As Table 1 makes clear, there was no significant differ-
ence between the CIN groups in terms of demographic 
characteristics (age, obstetric histories, smoking status, 
contraception methods and age of marriage).
Table 2 summarizes how carrying HPV16 and HPV18 and 
increasing the number of hrHPV types affected the CIN2-3 risk 
compared to CIN1.
The relationships between the number of concurrent 
hrHPV types and CIN2-3 risk is presented in Table 3. None 
of the relationships is statistically significant. In particular, 
having 4 or more concurrent hrHPV infections has very 
low odds ratio for CIN2-3 risk, but is not significant [OR: 
0.13 (0.02–1.07), p-value: 0.058].
Finally, the distribution of hrHPV types among CIN1 and 
CIN2-3 groups were summarized and compared in Table 4. 
HPV51 is significantly more common in patients with 
CIN1 compared to CIN2-3 group.
DISCUSSION
In this cross-sectional study, we evaluate the relationship 
between multiple concurrent HPV infections and precan-
cerous cervical lesions. The number of hrHPV genotypes is 
significantly lower in CIN2-3 patients compared to CIN1 pa-
tients. Hence, a higher number of hrHPV types is associated 
with lower CIN2-3 risk. The relationship gets stronger with 
concurrent phylogenetically independent HPV genotypes 
and with HPV infection with four or more concurrent hrHPV 
genotypes, but both of these relationships are statistically 
insignificant arguably due to the small sample sizes of the 
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Table 1. Demographic characteristics of cervical intraepithelial lesion groups
  CIN1 (n: 173) CIN2-3 (n: 76) p-value
Age ( mean ± SD)
39.3 ± 6.6 39.2 ± 6.5
0.850a
39 [34;44] 39 [33; 44]
Gravidy ( mean ± SD)
3.2 ± 1.6 2.9 ± 1.4
0.352a
3 [2; 4] 3 [2; 3.5]
Parity( mean ± SD)
2.4 ± 1.1 2.2 ± 1.2
0.164a
2 [2; 3] 2 [2; 3]
Education 0.458b
No school 15 (8.7%) 7 (9.2%)
Elementary school 32 (18.5%) 11 (14.5%)
Middle school 31 (17.9%) 8 (10.5%)
High school 71 (41.0%) 39 (51.3%)
University 24 (13.9%) 11 (14.5%)
Contraception 0.750b
No contraception 93 (53.8%) 36 (47.4%)
Oral contraceptives 35 (20.2%) 19 (25.0%)
Preservatives 24 (13.9%) 10 (13.2%)
Intrauterin devices 21 (12.1%) 11 (14.5%)
Tubal ligation 0 (0.0%) 0 (0.0%)
Smoker 0,447b
No 124 (71.7%) 58 (76.3%)
Yes 49 (28.3%) 18 (23.7%)
Age of marriage (mean ± SD)
22.6 ± 3.9 23.3 ± 4.6
0.401a
22 [20; 25] 22 [20; 26]
Number of HR-HPV genotypes
2.1 ± 1.2 1.7 ± 0.8
0.047a,*
2 [1; 3] 1 [1; 2]
CIN — cervical intraepithelial neoplasia; HR — high risk, HPV — Human Papilloma Virus; 
Data are presented as mean ± SD; median (interquartile range) or number (percentage) 
aMann–Whitney U-Test; bPearson Chi-Square Test; statistically significant comparisons are marked with*
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Figure 1. The distribution of single or multiple hrHPV infections related to various hrHPV genotypes
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Table 2. The relationship between different concurrent combinations of hrHPV genotypes and CIN2-3 risk in different samples
CIN2-3 risk (reference group: CIN1) 
(OIITNO: One increase in the number of)
No. of 
women Or (% 95 CI) p-value
Adjusted Or  
(% 95 CI)a p-value
In the total sample
OIITNO any HR-HPV type 249 0.72 (0.54–0.95) 0.022* 0.72 (0.54–0.96)b 0.025*
adding HPV16 249 1.34 (0.74–2.40) 0.331 1.02 (0.54–1.91)c 0.963
adding HPV18 249 0.75 (0.40–1.41) 0.375 0.58 (0.30–1.14)c 0.113
adding HPV16 + HPV18 68d 1.09 (0.38–3.14) 0.879 0.42 (0.11–1.64)c 0.213
OIITNO α9 species different than HPV16 249 0.95 (0.64–1.43) 0.813 1.02 (0.67–1.57)c 0.912
OIITNO α7 species different than HPV18 249 0.78 (0.42–1.43) 0.415 0.79 (0.43–1.45)c 0.442
OIITNO HR-HPV types different than HPV16 and 18 249 0.71 (0.54–0.95) 0.018* 0.71 (0.53–0.95)c 0.023*
Over the sample with HPV 16;
OIITNO any HR-HPV type 166 0.75 (0.54–1.03) 0.079 0.76 (0.55–1.05)c 0.092
adding HPV18 166 0.97 (0.39–2.42) 0.951 0.90 (0.35–2.28)c 0.817
OIITNO α9 species different than HPV16d 141e 1.15 (0.63–2.10) 0.656 1.78 (0.88–3.60)c 0.110
OIITNO α7 species different than HPV18e 141e 0.69 (0.30–1.62) 0.397 0.68 (0.29–1.59)c 0.376
OIITNO HR-HPV types different than HPV16 and 18 141e 0.73 (0.50–1.06) 0.096 0.75 (0.51–1.09)b 0.126
Over the sample with HPV18
OIITNO any HR-HPV type 65 0.96 (0.60–1.55) 0.875 0.92 (0.56–1.51)c 0.748
adding HPV16 65 1.62 (0.53–4.97) 0.398 1.41 (0.44–4.51)c 0.560
OIITNO α9 species different than HPV16 40f 1.24 (0.51–3.02) 0.644 1.63 (0.55–4.81)c 0.375
OIITNO α7 species different than HPV18 40f 0.98 (0.20–4.75) 0.984 1.05 (0.20–5.36)c 0.957
OIITNO HR-HPV types different than HPV16 and 18 40f 0.95 (0.49–1.87) 0.888 0.94 (0.47–1.88)b 0.856
Over the sample with HPV16 and HPV18
OIITNO α9 species different than HPV16 25 0.78 (0.20–3.09) 0.727 0.81 (0.19–3.56)c 0.783
OIITNO α7 species different than HPV18 25 0.67 (0.06–7.64) 0.744 1.99 (0.07–57.19)c 0.688
OIITNO HR-HPV types different than HPV16 and 18 25 0.69 (0.26–1.83) 0.453 0.68 (0.25–1.82)b 0.444
Over the sample without HPV16 and 18
OIITNO α9 species different than HPV16 43 0.54 (0.20–1.48) 0.232 0.20 (0.04–1.11)c 0.066
OIITNO α7 species different than HPV18 43 0.92 (0.28–3.00) 0.890 0.44 (0.07–2.90)c 0.395
Over the sample with only α9 species
adding HPV 16 102 1.24 (0.40–3.90) 0.713 1.23 (0.39–3.86)c 0.728
OIITNO α9 species different than HPV16 102 1.18 (0.61–2.29) 0.629 1.47 (0.67–3.24)c 0.342
adding HPV 18 147 0.75 (0.35–1.60) 0.448 0.95 (0.41–2.21)c 0.896
OIITNO α7 species different than HPV18 123 0.98 (0.45–2.12) 0.954 0.98 (0.45–2.16)c 0.968
Over the sample with only α9 species different than HPV16
adding HPV18 44 0.60 (0.15–2.41) 0.471 0.54 (0.06–4.86)c 0.581
Over the sample with only α7 species
adding HPV 16 112 1.29 (0.53–3.18) 0.578 1.33 (0.41–4.25)c 0.636
OIITNO α9 species different than HPV16 59 0.79 (0.37–1.70) 0.542 0.81 (0.37–1.78)c 0.596
adding HPV 18 31 0.13 (0.02–0.89) 0.038* 0.07 (0.002–2.71)c 0.156
OIITNO α7 species different than HPV18 31 2.99 (0.70–12.68) 0.139 0.63 (0.04–9.92)c 0.743
Over the sample with only α7 species different than HPV18
adding HPV16 76 0.25 (0.04–1.43) 0.119 0.15 (0.02–1.41)c 0.097
CIN – cervical intraepithelial neoplasia; HR – high risk; HPV — Human Papilloma Virus; OR — Odds ratio 
aOdds ratios were adjusted for all demographic variables having effect on the CIN2-3 risk with p-value lower than 0.100 
bThe logistic regression model was adjusted for only parity according toa 
cThe logistic regression model was adjusted for parity and the number of HPV types except the investigated HPV types in each relevant analysis, according toa 
dWomen having only one of HPV 16 or HPV 18 excluded from the sample 
ePatients with HPV 18 were excluded from the sample 
fPatients with HPV 16 were excluded from the sample 
Note: Statistically significant comparisons are marked with*. α9 species include HPV16, 31, 33, 35, 52 and 58. α7 species include HPV18, 39, 45, 59 and 68
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subgroups. The evidence also suggests that the presence of 
an additional HPV 16 is associated with higher CIN2-3 risk 
for all different combinations of HPV genotypes.
HPV genotyping is part of the cervical cancer screening 
programs in many countries [8]. The epidemiological studies 
show that the prevalence of HPV types in each population 
is different [9]. Consequently, studies on HPV have limited 
generalizability except for the pathophysiologic interpreta-
tions. However, as most high-grade lesions are associated 
with HPV 16 and 18 universally, this relationship wastaken 
into account by diagnostic guidelines.
In this study, HPV 16 was found to be the most fre-
quently genotype in both high-grade and low-grade le-
sions. In patients with high-grade lesions, HPV 31 and HPV 
18 were found to be the second and third most frequent. For 
low-grade lesions, HPV 51 was the second most common 
(28.9%) and its frequency was significantly higher com-
pared to patients with high-grade lesions (6.6%). Consistent 
with our findings, an epidemiologic study of over 1 million 
women in Turkey found HPV 51 to be the second most com-
mon type of HPV in non HPV 16,18 positive women [10]. It 
can also be conjectured that the HPV 51 genotype might 
be cleansed by the immune system during the progres-
sion of cervical intraepithelial lesion and therefore is not 
an important threat for precancerous lesions. These patterns 
should be taken into consideration when developing new 
and broader spectrum vaccines for immunization in the near 
future for the Turkish population.
There is a limited number of studies on concurrent HPV 
infections. A major reason for this was the difficulties associated 
with detecting other genotypes except HPV 16 and 18. Thanks 
to the polymerase chain reaction (PCR)-based assays devel-
oped especially in the last decade, the rate of detection of 
multiple HPV infections rose between 24.8% to 52.6% for differ-
ent kits [11]. The improvements in detection in turn paved the 
way for investigating the impact of concurrent HPV genotypes 
on the risk of precancerous lesions and carcinoma of cervix.
Our findings suggest that increases in the number of 
hrHPV infection types decrease the frequency of CIN2-3. The 
mean number of hrHPV types are significantly higher in CIN 
1 patients. The rate of multiple concurrent HPV infections 
was 48.7% in the CIN2-3 group and 58.4% in the CIN1 group. 
The 10% difference between the two groups suggests that 
some HPV genotypes are cleared by the immune system 
in the stage of progression of low-grade cervical lesions to 
high-grade lesion and the women with a lower number of 
hrHPV types might represent a sample with persistent HPV 
infection. The frequency of women with short term sexual 
intercourse is possibly higher in the low-grade lesion group.
The relationships between the number of hrHPV types 
and precancerous cervical lesions in various subpopulations 
are presented in Table 2. Arguably due to the small sample 
sizes, most of the relationships are statistically insignificant. 
An increase in α7 species of hrHPV types in the sample with 
α9 species lowers the risk of CIN2-3, probably because they 
are phylogenetically independent from each other. For all 
samples and hrHPV combinations, the addition of HPV 16 is 
associated with a higher risk of CIN2-3.
Table 3. The relationship between the number of concurrent hrHPV 
types and CIN2-3 risk
Number  
of HPV types
CIN1  
(n: 173)
CIN2-3  
(n: 76) Or (% 95 CI) p-value
n (%) n (%)
1 72 (41.6) 39 (51.3) 1.00 (referent)
0.611
2 50 (28.9) 23 (30.3) 0.85 (0.45–1.59)
2 50 (28.9) 23 (30.3) 1.00 (referent)
0.764
3 32 (18.5) 13 (17.1) 0.88 (0.39–1.99)
3 32 (18.5) 13 (17.1) 1.00 (referent)
0.058
≥ 4 19 (11.0) 1 (1.3) 0.13 (0.02–1.07)
Single 72 (41.6) 39 (51.3) 1.00 (referent)
0.157
Multiple 101 (58.4) 37 (48.7) 0.68 (0.39–1.16)
Data are presented as number (percentage) 
*Reference group for calculating odds ratios are women with CIN1
Table 4. Comparison and distribution of hrHPV types for different 
types of cervical lesions
  CIN1 (n: 173) CIN2-3 (n: 76) p-value
HPV16 112 (64.7%) 54 (71.1%) 0.331a
HPV18 48 (27.7%) 17 (22.4%) 0.374a
HPV31 30 (17.3%) 19 (25.0%) 0.162a
HPV33 24 (13.9%) 6 (7.9%) 0.182a
HPV35 8 (4.6%) 4 (5.3%) 0.760b
HPV39 13 (7.5%) 1 (1.3%) 0.070b
HPV45 24 (13.9%) 8 (10.5%) 0.467a
HPV51 50 (28.9%) 5 (6.6%) 0,009a,*
HPV52 16 (9.2%) 7 (9.2%) 0.992a
HPV53 3 (1.7%) 0 (0.0%) 0.555b
HPV56 1 (0.6%) 3 (3.9%) 0.086b
HPV58 10 (5.8%) 1 (1.3%) 0.180b
HPV59 2 (1.2%) 0 (0.0%) 1.000b
HPV66 8 (4.6%) 3 (3.9%) 1.000b
HPV68 6 (3.5%) 1 (1.3%) 0.679b
Data are presented as number (percentage) 
aPearson Chi-Square Test; bFisher’s Exact Test; statistically significant 
comparisons are marked with* 
Note: Patients might have more than one HPV genotype
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Because the present study is cross sectional, it does 
not allow establishing the causation between the number 
of hrHPV types and CIN2-3 risk. For this purpose, further 
clinical studies with cohort design are needed. The study, 
however, provides clues on the interactions between hrHPV 
types and CIN.
In the literature there are epidemiologic studies investi-
gating multiple HPV infections and cervical carcinogenesis 
risk based on PAP-smear or colposcopy results. Salazar et al. 
reports that different combinations of HPV infections are 
associated with different risk ratios for high grade cervical 
lesions. The paper conjectures that intergenotypic com-
petition or more effective immune response triggered by 
multiple infections might be decreasing the precancerous 
lesions’ risk [12]. The limitation of the study was that the 
risks were not adjusted for demographic characteristics 
and the PAP-smear test used in study is underpowered 
to compare cervical lesions with pathological colposcopy 
evaluations. Dickson et al.’s study which was also based on 
PAP smear results found that multiple HPV type infections 
increase abnormal cytology risk relative to single type HPV 
infections [13]. Morrison et al. [14] and Chaturverdi et al. [3] 
find that LSIL (low-grade squamous intraepithelial lesion) 
risk increases substantially when HPV-16 and other HPV 
types are not present alone. Fife et al. [15] suggests that HPV 
types 51, 52, 56, and 58 might interact with HPV-16 to cause 
dysplasia or cancer. Our study also finds that the presence 
of HPV16 alongside with the other hrHPV types have larger 
odds ratios than 1 for CIN2-3. However, our other results 
seem to conflict with them and we can’t generalize this 
situation for other hrHPV infections based on our subgroup 
analysis (Tab. 2).
Based on colposcopy results, Spinillo et al. in 2014 re-
ports that multiple type HPV infections increases the risk of 
CIN3+ in both HPV 16 positive and negative women [16]. 
Recently, Debrot et al. conducted a follow-up study for 
assessing the CIN2-3 risk, but the study had small sample 
size and did not adjust for demographic characteristics [17].
The strengths of the present study are that it relies on 
colposcopy, and assesses the outcome based on the in-
crease in the number of HPV infections while other studies 
mostly compare cervical lesions based on the presence of 
single or multiple infections. On the other hand, because the 
study is cross-sectional and does not track the persistence 
of HPV infections, it cannot establish causation. As for the 
sample size, it is large enough to assess the impact of the 
number of HPV types on CIN2-3 risk, but not large enough 
to conduct subgroup analysis without type 2 errors.
CONCLUSIONS
All in all, the number of hrHPV types don’t have a clear re-
lationship with CIN2-3 risk. Some hrHPVs may increase while 
others may decrease the risk, and the specific combinations 
of the types appear to matter.Further cohort studies with 
larger samples are needed to establish these relationships 
in a clear way. 
IRB status: Bakirkoy Dr. Sadi Konuk Training and Research 
Hospital, Local Ethics Committee, Project no: 2018/410 De-
cision no: 2018-19-14
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